CYP1A2 contributes to the metabolism of mefloquine: Exploration using in vitro metabolism and physiologically-based pharmacokinetic modelling
Open Access
- 8 March 2025
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (4) , 100060
Abstract
No abstract availableKeywords
Funding Information
- Universityof CapeTown
- National Research Foundation
- University of Capetown
- Medicines for Malaria Venture
- South African Medical Research Council
This publication has 40 references indexed in Scilit:
- Development and application of a PBPK modeling strategy to support antimalarial drug developmentCPT: Pharmacometrics & Systems Pharmacology, 2023
- Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumptionDrug Metabolism and Pharmacokinetics, 2021
- Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitroPsychopharmacology, 2014
- Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2European Journal of Clinical Pharmacology, 2012
- Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Mefloquine HydrochlorideJournal of Pharmaceutical Sciences, 2011
- Stereoselective pharmacokinetics of mefloquine in young childrenEuropean Journal of Clinical Pharmacology, 1996
- Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteersEuropean Journal of Clinical Pharmacology, 1994
- Stereoselective Pharmacokinetics of Mefloquine in Healthy Caucasians after Multiple DosesJournal of Pharmaceutical Sciences, 1994
- Mefloquine metabolism by human liver microsomesBiochemical Pharmacology, 1992
- Effect of smoking on caffeine clearanceClinical Pharmacology & Therapeutics, 1978